Exploration of breath analysis to monitor therapeutic response in mesothelioma patients Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Exhaled breath analysis allows exclusive screening for malignant pleural mesothelioma. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Evaluation of chemotherapy response determined by volumetric method in malignant pleural mesothelioma and its effect on determination to survival Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007
Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Source: Eur Respir J 2011; 37: 162-168 Year: 2011
Improving the tuberculous and malignant pleural effusions diagnosis. A low cost model based on a multivariate analysis Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Time to diagnosis and time to therapy in patients with malignant pleural mesothelioma (MPM) compared to patients with lung cancer in Denmark 2007 to 2011. A quality assurance analysis Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012
Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019
PET predicts survival in malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=290 Year: 2007
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
A comparative study of conventional cytology and cell block method in the diagnosis of malignant pleural effusion. Source: International Congress 2018 – Lung cancer: new tools for diagnosis and patient assessment Year: 2018
A complex course in a pleural mesothelioma patient Source: International Congress 2019 – Lung cancer Grand Round Year: 2019
Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005
Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005